A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
A Phase 1/2, First-in-Human, Double-Masked, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
Objectives:
Primary
- To determine the safety and tolerability of escalating doses of RU-101 for 4 weeks in patients with severe dry eye
Secondary
- To explore the efficacy of RU-101
- To explore optimal endpoints for future studies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Virginia
-
Norfolk, Virginia, United States, 22655-5342
- Virginia Eye Consultants
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged 18 to 80 years.
- Patients have had dry eye symptoms at least 4 months.
Patients have the following signs in the worst eye:
- Corneal staining score with fluorescein staining ≥ 6/15 with at least one in the central
- Conjunctival staining score with Lissamine Green ≥ 2/18
- Patients who had been receiving treatment with eye drops of artificial tears, Restasis, or topical steroids but have had insufficient efficacy or have found these products to be intolerable. If using Restasis or topical steroids, patients must agree to a 30-day washout period prior to the first IP dose (Day 0).
- Female patients of child bearing potential must agree to have a urine pregnancy test performed at Screening (must be negative) and agree to use a medically acceptable form of birth control (e.g., intrauterine device, birth control pill, patch or subcutaneous implant, condoms, diaphragm, or abstinence) throughout the duration of IP instillation. Women considered capable of becoming pregnant include all females who have experienced menarche and who have not experienced menopause (as defined by amenorrhea for > 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).
Exclusion Criteria:
- Presence of anterior eye diseases except dry eye.
- Intraocular pressure ≥ 22 mmHg at Screening.
- Use of any ophthalmic solutions (including over-the-counter [OTC] solutions), serum eye drops, or contact lenses during the Treatment Phase. Artificial tears are allowed during the Screening Phase but must not be used from the first dose (Day 0) through the Treatment Phase.
- Use of eye drops of Restasis or topical steroids within 30 days of the first dose (Day 0).
- Use of antihistamines, beta blockers, tricyclic antidepressants, or antidepressants with anticholinergic side effects during the Treatment Phase.
- Patients with previous corneal transplantation or laser-assisted in situ keratomileusis (LASIK).
- Presence of graft-versus-host disease (GVHD).
- Patients who have had other ocular surgery within 3 months prior to the first dose.
- Patients with punctal plugs or punctal cautery < 3 months prior to the first dose.
- Patients with severe dry eye due to Stevens-Johnson disease or ocular cicatricial pemphigoid.
- History of allergy to human serum protein products and/or any history of allergy to yeast.
- History of allergies to recombinant products, ophthalmic solutions, any constituents of RU 101, or any solutions planned for use in this study.
- Any significant chronic illness that, in the opinion of the Principal Investigator (PI), could interfere with the study parameters.
- Use of any investigational product or device within 30 days prior to the Screening Visit or during the study.
- Known history of alcohol and/or drug abuse within the past 12 months, which in the opinion of the PI could interfere with study compliance, outcome measures including safety parameters, and/or the general medical condition of the patient.
- Those unable in the opinion of the PI to comply fully with the study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye).
In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
|
Recombinant human serum albumin
|
|
Experimental: RU-101
In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye).
In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
|
Recombinant human serum albumin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occular Adverse Events
Time Frame: 56 dyas (stage1) 112 days (stage 2)
|
The number of participants with a change from baseline in the following symptoms:
|
56 dyas (stage1) 112 days (stage 2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptoms
Time Frame: 28days (stage 1) 3 months (stage2)
|
The number of participants with a change from baseline in the following symptoms:
|
28days (stage 1) 3 months (stage2)
|
|
Signs
Time Frame: 28days (stage 1) 3 months (stage2)
|
The number of participants with a change from baseline in the following signs:
|
28days (stage 1) 3 months (stage2)
|
|
Non-Occular Adverse Events
Time Frame: 56 dyas (stage1) 112 days (stage 2)
|
Number of AEs will be measured (vital signs, physical examination results, safety laboratory results, 12-lead electrocardiogram (ECG), and IP comfort assessment.
|
56 dyas (stage1) 112 days (stage 2)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: John Sheppard, MD, Virginia Ehe Consultants
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RU-101-C001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.